On August 7, Oklo Inc. rose 5.85% in regular trading, trading at $45.24/share, with turnover of $70.9955 million.
On the news front, the U.S. Department of Energy announced that Oklo's small nuclear reactor has achieved criticality, marking a critical milestone on the path to advanced nuclear energy commercialization. Previously in July, Oklo's Groves Isotope Test Reactor had received DOE startup authorization and safety analysis approval, and the company has now formally reached its first criticality target.
Simultaneously, the company released Q2 earnings showing revenue of $1.2 million, dramatically exceeding the analyst consensus estimate of approximately $126,250. However, the per-share loss of $0.28 was wider than the $0.16 loss expected by analysts, representing a 55.56% increase in losses compared with $0.18 per share a year ago. Notably, CEO Jacob DeWitte and COO Caroline Cochran have each filed Form 144 to sell 400,000 shares, which may weigh on sentiment going forward.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments